Enovis (ENOV) AI Stock Analysis

• Market Cap: $1.63B
• Dividend Yield: N/A
• Average Volume (3M): 1.68M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: 14.40%
• EPS Growth: -662.25%
• Country: US
• Employees: 7,367
• Sector: Healthcare
• Sector Strength: 38
• Industry: Industrial - Machinery
• EPS (TTM): 0.79
• Shares Outstanding: 57,159,800
• 10 Day Avg. Volume: 1,338,306
• 30 Day Avg. Volume: 1,683,401
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.95
• Price to Sales (P/S): 1.15
• P/FCF Ratio: -36.09
• Enterprise Value/Market Cap: 2.06
• Enterprise Value/Revenue: 1.56
• Enterprise Value/Gross Profit: 2.75
• Enterprise Value/Ebitda: -7.09
• 1Y Price Target: $51.50
• Price Target Upside: 81.08% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 46 Neutral
• Price Target: $26.00 ▼(-8.58% Downside)

The overall stock score of 44 reflects the significant financial and valuation challenges faced by Enovis, with consistent net losses and negative cash flows being major concerns. While the earnings call provided some positive developments with growth in key segments, the technical analysis indicates bearish momentum and oversold conditions.

Positive Factors

Financial Performance

Enovis reported a solid Q2 beat, with 11% reported growth for Recon and 5% reported growth for P&R, driven by strong growth in global extremities and hips & knees.

Guidance and Strategy

ENOV raised its FY25 guidance across revenue, organic growth, EBITDA, and EPS, supported by operational execution, FX tailwinds, and decreased expected tariff impacts.

Valuation

ENOV is working to create a cohesive unit of its Recon acquisitions, driving both an organic R&D engine and operational discipline, with the stock trading at less than half the valuation of its mid-cap MedTech peers, suggesting it is significantly undervalued.

Negative Factors

Organic Growth

Organic revenue growth slowed to 5.1% in 2Q25 from 10.4% in 1Q25.

Peer Comparison

The price target is lowered to $49 due to peer multiple contraction.

Product Launch Delays

The next-gen ARVIS launch has been delayed by approximately 6 months to incorporate enhancements, although surgeon excitement around the platform remains high.

Enovis Business Overview & Revenue Model

Company Description

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.

How the Company Makes Money

Enovis generates revenue through multiple key streams, primarily by selling medical devices and orthopedic solutions to hospitals, clinics, and healthcare professionals. The company's revenue model includes direct sales of products, as well as potential recurring revenue from post-operative care solutions and digital health services. Significant partnerships with healthcare providers and distributors enhance its market reach and facilitate the introduction of innovative products. Additionally, Enovis may engage in research and development collaborations that can lead to new product offerings and expand its revenue opportunities.

Enovis Financial Statement Overview

Summary

Enovis faces significant financial challenges with declining revenues, consistent net losses, and negative free cash flow. Despite maintaining a strong equity ratio and low leverage, operational inefficiencies are prevalent, impacting overall profitability and cash flow generation.

Income Statement

The income statement shows a concerning trend with declining revenues and consistent net losses. The TTM revenue growth is slow at 2.02%. Gross profit margins have remained strong at 52.62%, but the net profit margin is negative, indicating operational inefficiencies with a TTM net margin of -37.65%. The EBIT and EBITDA margins are also negative, reflecting significant operating challenges.

Balance Sheet

Enovis maintains a moderate debt-to-equity ratio of 0.03, showing effective management of debt. However, the return on equity is negative at -30.92% for TTM, signaling poor returns to shareholders. The equity ratio is strong at 53.69%, indicating a solid base of equity relative to total assets.

Cash Flow

The cash flow analysis reveals a struggle with free cash flow, which is negative and has decreased over time, with a TTM free cash flow of -$38.98 million. Despite positive operating cash flows of $148.06 million in TTM, the free cash flow to net income ratio remains unfavorable due to consistent net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.15B	2.11B	1.71B	1.56B	3.85B	3.07B
Gross Profit	1.22B	1.18B	990.78M	869.38M	1.61B	1.29B
EBITDA	-471.91M	-481.03M	169.92M	225.78M	95.03M	180.05M
Net Income	-809.46M	-825.49M	-33.26M	-38.19M	98.69M	64.08M
Balance Sheet
Total Assets	4.88B	4.72B	4.51B	4.27B	8.52B	7.35B
Cash, Cash Equivalents and Short-Term Investments	38.46M	48.17M	36.19M	24.30M	680.25M	97.07M
Total Debt	1.46B	1.40B	536.42M	310.54M	2.16B	2.37B
Total Liabilities	2.25B	2.15B	1.09B	823.45M	3.85B	3.76B
Stockholders Equity	2.62B	2.56B	3.42B	3.45B	4.62B	3.54B
Cash Flow
Free Cash Flow	-38.98M	-67.21M	12.77M	-161.31M	251.86M	187.15M
Operating Cash Flow	148.06M	113.50M	134.99M	-55.86M	356.10M	301.94M
Investing Cash Flow	-218.15M	-955.47M	-242.47M	-176.39M	-320.48M	-175.08M
Financing Cash Flow	33.47M	846.82M	127.80M	-465.13M	584.91M	-131.65M

Enovis Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 28.44
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENOV, the sentiment is Neutral. The current price of 28.44 is above the 20-day moving average (MA) of 27.83, below the 50-day MA of 30.52, and below the 200-day MA of 38.38, indicating a neutral trend. The MACD of -1.15 indicates Negative momentum. The RSI at 48.52 is Neutral, neither overbought nor oversold. The STOCH value of 52.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ENOV.

Enovis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TNC	67 Neutral	$1.48B	25.03	9.51%	1.45%	-0.38%	-44.93%
SXI	66 Neutral	$2.26B	40.44	8.37%	0.66%	9.64%	-24.68%
CXT	66 Neutral	$3.48B	23.17	13.98%	1.09%	10.28%	-16.81%
EPAC	64 Neutral	$2.17B	24.75	21.91%	0.10%	2.82%	7.50%
HI	54 Neutral	$1.39B	―	-18.22%	4.55%	0.31%	-423.59%
Sector *	51 Neutral	$7.35B	-0.20	-44.53%	2.35%	30.18%	-1.17%
ENOV	46 Neutral	$1.63B	―	-28.31%	―	14.40%	-662.25%

Enovis Corporate Events

Enovis Holds Annual Meeting, Elects Board Directors

On May 21, 2025, Enovis Corporation held its Annual Meeting of Stockholders, where three proposals were presented. The stockholders elected nine directors to the board, ratified Ernst & Young LLP as the independent registered public accounting firm for 2025, and approved the executive compensation of the named executive officers.

The most recent analyst rating on (ENOV) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Enovis stock, see the ENOV Stock Forecast page.